Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
John T. Isaacs(Brady (Norway)), Tomas Leanderson(Lund University), David Z. Qian(Unknown), Susan L. Dalrymple(Johns Hopkins University), Jason B. Garrison(University of Kentucky), Natasha Kyprianou(Icahn School of Medicine at Mount Sinai), Роберто Пили(Jacobs Institute), Anders Björk(Active Biotech (Sweden)), Anders Olsson(Linköping University)
Cited by 87
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
|PLoS Biology|2009|358
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
|Cancer Research|2010|350